MEI Pharma, Inc. - Common Stock (MEIP)

Darwin Financial's Joshua Robinson talks to Benzinga about the firm's latest commodities deal, and more M&A news from this past week.

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga's Deal Dispatch has the latest M&A updates.

The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive.

MEIP stock results show that MEI Pharma beat analyst estimates for earnings per share the third quarter of 2024.

Companies Reporting Before The Bell • Ferguson (NYSE:FERG) is estimated to report quarterly earnings at $2.46 per share on revenue of $7.60 billion.

Infinity Pharmaceuticals Inc (NASDAQ: INFI) announced further design features of its Phase 2 MARIO-8 study in Squamous Cell Cancer of the 

MEI Pharma Inc (NASDAQ: MEIP) announced an update to the Phase 1 study of voruciclib, an orally administered cyclin-dependent kinase 9 inhibitor, in patients with relapsed and refractory (R/R) acute myeloid leukemia (AML) 

Potential short squeeze plays gained steam in 2021, continued through 2022, and remain a focus of new traders looking for the next huge move. High short interest and high cost to borrow are among the common traits that could lead to a short squeeze.

MEI Pharma (NASDAQ: MEIP) shares are trading lower by roughly 2.54% to $4.68 Monday morning, though rebounding off the session low of $4.30, after the company announced and effected a 1-for-20 reverse stock split.

The Dow Jones closed slightly higher on first trading day of March. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Gainers